JP2022532379A5 - - Google Patents

Info

Publication number
JP2022532379A5
JP2022532379A5 JP2021568115A JP2021568115A JP2022532379A5 JP 2022532379 A5 JP2022532379 A5 JP 2022532379A5 JP 2021568115 A JP2021568115 A JP 2021568115A JP 2021568115 A JP2021568115 A JP 2021568115A JP 2022532379 A5 JP2022532379 A5 JP 2022532379A5
Authority
JP
Japan
Prior art keywords
alkyl
formula
pharmaceutically acceptable
hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021568115A
Other languages
English (en)
Japanese (ja)
Other versions
JP7812051B2 (ja
JP2022532379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032903 external-priority patent/WO2020232255A1/en
Publication of JP2022532379A publication Critical patent/JP2022532379A/ja
Publication of JP2022532379A5 publication Critical patent/JP2022532379A5/ja
Priority to JP2025280205A priority Critical patent/JP2026048976A/ja
Application granted granted Critical
Publication of JP7812051B2 publication Critical patent/JP7812051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021568115A 2019-05-14 2020-05-14 神経変性および代謝障害の処置のための化合物 Active JP7812051B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025280205A JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847600P 2019-05-14 2019-05-14
US62/847,600 2019-05-14
PCT/US2020/032903 WO2020232255A1 (en) 2019-05-14 2020-05-14 Compounds for the treatment of neurodegenerative and metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025280205A Division JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Publications (3)

Publication Number Publication Date
JP2022532379A JP2022532379A (ja) 2022-07-14
JP2022532379A5 true JP2022532379A5 (enExample) 2023-07-12
JP7812051B2 JP7812051B2 (ja) 2026-02-09

Family

ID=70978576

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568115A Active JP7812051B2 (ja) 2019-05-14 2020-05-14 神経変性および代謝障害の処置のための化合物
JP2025280205A Pending JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025280205A Pending JP2026048976A (ja) 2019-05-14 2025-12-24 神経変性および代謝障害の処置のための化合物

Country Status (9)

Country Link
US (1) US12590094B2 (enExample)
EP (1) EP3968981A1 (enExample)
JP (2) JP7812051B2 (enExample)
CN (1) CN114173774A (enExample)
AU (2) AU2020274186A1 (enExample)
BR (1) BR112021022734A2 (enExample)
CA (2) CA3297266A1 (enExample)
IL (2) IL288001B2 (enExample)
WO (1) WO2020232255A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021377893A1 (en) * 2020-11-12 2023-06-22 Scripps Research Institute, The Nicotinamide dinucleotide (nad) detection and quantification
JP2024501625A (ja) * 2020-12-11 2024-01-15 ザ スクリプス リサーチ インスティテュート 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用
IL303924A (en) * 2020-12-18 2023-08-01 Scripps Research Inst Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN117355300A (zh) * 2021-01-15 2024-01-05 佛罗里达大学研究基金会公司 化合物及其用于治疗神经退行性、退行性以及代谢疾病的用途
WO2022165173A1 (en) * 2021-01-28 2022-08-04 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
JP2024516827A (ja) 2021-04-30 2024-04-17 マインド メディシン， インコーポレイテッド Ｌｓｄ塩結晶形態
WO2022235531A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Movement disorders
KR20240007258A (ko) * 2021-05-13 2024-01-16 유니버시티 오브 싸우스 캐롤라이나 리실 옥시다제의 억제제로서 비티아졸 유도체
AU2022331315B2 (en) 2021-08-19 2025-10-16 Definium Therapeutics US, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
CN116036279A (zh) * 2022-07-27 2023-05-02 上海交通大学医学院附属新华医院 Echs1抑制剂的用途
CN121002020A (zh) * 2022-12-13 2025-11-21 韦夫布雷克治疗有限责任公司 治疗与蛋白质错误折叠相关的病症的化合物、组合物和方法
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
EP4643856A1 (en) * 2024-05-03 2025-11-05 Centre National de la Recherche Scientifique Carbazole derivatives used as neuroprotectants and in the treatment of disorders with reduced nad metabolism

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6903101B1 (en) * 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
JP4852540B2 (ja) * 2004-06-30 2012-01-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのフタラジン誘導体
EP1865775A1 (en) * 2005-04-06 2007-12-19 Irm, Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
WO2016085990A1 (en) * 2014-11-24 2016-06-02 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
WO2017160864A1 (en) * 2016-03-14 2017-09-21 Board Of Regents, The University Of Texas System Hydralazine and active derivatives thereof for neuronal cell survival and regeneration

Similar Documents

Publication Publication Date Title
ES2211904T3 (es) Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
JP7374149B2 (ja) タンパク質症を処置するための方法
KR102271794B1 (ko) 항암 활성을 나타내는 벤젠 설폰아미드 티아졸 화합물
CA3092749A1 (en) Deuterated compounds as rock inhibitors
WO2006064757A1 (ja) アミノカルボン酸誘導体およびその医薬用途
EA011689B1 (ru) Имидазольные соединения для лечения нейродегенеративных расстройств
CA2113568A1 (en) 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
US7468386B2 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20210332009A1 (en) Benzene derivative
JP2007508301A5 (enExample)
US12227479B2 (en) Dihydropyridines for the treatment of cognitive impairment or traumatic brain injury
CN112714761A (zh) 用作分子伴侣介导的自噬调节剂的化合物
US20170233382A1 (en) Processes for the preparation of a bace inhibitor
JP2002538117A (ja) 肥満の予防または治療のための医薬の製造のための多環２−アミノチアゾール系の使用
JP2002538148A (ja) 多環２−アミノチアゾール系、その製造方法およびそれを含む医薬
EP3625230A1 (en) Prodrugs for the treatment of disease
KR20190114955A (ko) Mtor-deptor 상호작용의 저해제 및 이의 사용 방법
CA2752198C (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
EP1960387B1 (fr) Derives de isoquinoline et benzo[h]isoquinoline, leur preparation et leur utilisation en therapeutique en tant qu antagonistes du recepteur de l histamine h3
US9908843B2 (en) Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors
JP4216337B2 (ja) ベンゾ［ｇ］キノリン誘導体
JP2004123716A (ja) 化学物質に起因する肝障害の予防及び／又は治療のための医薬
US10844018B2 (en) Pyridoxine derivative for treatment of epilepsy
RU2811803C9 (ru) Производное бензола
WO2022171560A1 (en) 6-methyluracil derivatives with anticholinesterase activity and their use